Monthly Archives: July 2023

• 

2022 National Cancer Patient Experience Survey

By Sharon Deveson Kell|2023-07-26T08:07:19+00:0026 Jul 2023|Cancer news|

The latest results from the 2022 National Cancer Patient Experience [...]

Read More

Comments Off on 2022 National Cancer Patient Experience Survey

• 

Partial nephrectomy versus ablation for early stage kidney cancer in the elderly

By Sharon Deveson Kell|2023-07-25T13:54:31+00:0025 Jul 2023|Surgery|

A recent study compared the success of robot-assisted partial nephrectomy [...]

Read More

Comments Off on Partial nephrectomy versus ablation for early stage kidney cancer in the elderly

• 

Early cancer detection test using ctDNA

By Sharon Deveson Kell|2023-07-19T07:54:45+00:0019 Jul 2023|Cancer news|

The study of pieces of tumour DNA in the blood [...]

Read More

Comments Off on Early cancer detection test using ctDNA

• 

WECAN Academy 2023

By Sharon Deveson Kell|2023-07-19T08:17:15+00:0019 Jul 2023|Patient advocacy|

At the start of July, one of the Action Kidney [...]

Read More

Comments Off on WECAN Academy 2023

• 

Cancer Research UK: Workshop on diagnostic tests for cancer

By Sharon Deveson Kell|2023-07-18T07:55:27+00:0018 Jul 2023|Patient advocacy|

Sharon Deveson Kell was invited by Cancer52 to represent the [...]

Read More

Comments Off on Cancer Research UK: Workshop on diagnostic tests for cancer

• 

The Big Cancer52 Conversation

By Sharon Deveson Kell|2023-07-18T08:07:26+00:0018 Jul 2023|Patient advocacy|

Sharon Deveson Kell represented the kidney cancer community at the [...]

Read More

Comments Off on The Big Cancer52 Conversation

• 

Pembrolizumab plus lenvatinib as first-line treatment for advanced non-clear cell kidney cancer

By Sharon Deveson Kell|2023-07-18T06:58:37+00:0018 Jul 2023|Drug treatments|

Immunotherapy combinations are becoming the standard treatment after surgery for [...]

Read More

Comments Off on Pembrolizumab plus lenvatinib as first-line treatment for advanced non-clear cell kidney cancer

• 

Tivozanib for heavily pre-treated patients with advanced kidney cancer

By Sharon Deveson Kell|2023-07-04T07:27:13+00:004 Jul 2023|Drug treatments|

TIVO-3 was a phase 3 clinical trial that compared tivozanib, [...]

Read More

Comments Off on Tivozanib for heavily pre-treated patients with advanced kidney cancer